Login to Your Account



Broader IP Flexibility Urged for Drugmakers

By Donna Young


Wednesday, October 15, 2008
WASHINGTON - The pharmaceutical and biotechnology industries' heavy reliance on patents and aggressive enforcement of intellectual property (IP) are creating an environment of intimidation that prevents scientists from using tools vital to innovation, researchers from McGill and Duke universities contended Tuesday during a Capitol Hill briefing. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription